Impact of changes in controlled drugs legislation on benzodiazepine receptor agonist prescribing in Ireland: a repeated cross-sectional study
Open Access
- 7 January 2021
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 77 (6) , 903-912
Abstract
Purpose: To examine the impact of new controlled drugs legislation introduced in May 2017 on benzodiazepine receptor agonist (BZRA) prescribing in Ireland. Methods: A repeated cross-sectional analysis was conducted using publically available monthly pharmacy claims data from the General Medical Services (GMS) database. The study population comprised all GMS-eligible individuals aged ≥ 16 years from January 2016 to September 2019. Monthly prevalence rates of individuals receiving BZRA prescriptions per 10,000 eligible population were calculated and trends examined over time. Segmented linear regression of prevalence rates was used to examine changes before and after introduction of the legislation stratified by gender and age groups. Regression coefficients (β) and 95% confidence intervals (CIs) for monthly change were calculated. Results: Pre-legislation (January 2016 to April 2017), there was a significant monthly decline in benzodiazepine prevalence rate (β = − 1.18; 95% CI − 1.84, − 0.51; p < 0.001) but no significant change in Z-drug prescribing. Post-legislation (May 2017 to September 2019), increases in prevalence rates were observed for benzodiazepines (β = 1.04; 95% CI 0.17, 1.92; p = 0.021) and Z-drugs (β = 1.04; 95% CI 0.26, 1.83; p = 0.010). Post-legislation trends showed increases in BZRA prevalence rates among the youngest subgroup (16–44 years), with variable changes in the middle-aged subgroup (45–64 years) and no changes in the oldest subgroup (≥ 65 years). Conclusions: This study indicates that introduction of new legislation had limited impact on BZRA prescribing on the main public health scheme in Ireland. Interventions targeting specific population subgroups may be required to achieve sustained reductions in prescribing.Keywords
Funding Information
- Health Research Board (RL-15-1579)
This publication has 33 references indexed in Scilit:
- Deprescribing benzodiazepines and Z-drugs in community-dwelling adults: a scoping reviewBMC Pharmacology and Toxicology, 2015
- Benzodiazepine Use in the United StatesJAMA Psychiatry, 2015
- STOPP/START criteria for potentially inappropriate prescribing in older people: version 2Age and Ageing, 2014
- Use of benzodiazepines and related drugs in Manitoba: a population-based studyCMAJ Open, 2014
- General practitioners’ experiences and perceptions of benzodiazepine prescribing: systematic review and meta-synthesisBMC Family Practice, 2013
- The intended and unintended consequences of benzodiazepine monitoring programmes: a review of the literatureJournal of Clinical Pharmacy and Therapeutics, 2011
- Usage of benzodiazepines: A reviewInternational Journal of Psychiatry in Clinical Practice, 2010
- Segmented regression analysis of interrupted time series studies in medication use researchJournal of Clinical Pharmacy and Therapeutics, 2002
- Benzodiazepines with different half-life and falling in a hospitalized populationJournal of Clinical Epidemiology, 2000
- Intravenous and other novel abuses of benzodiazepines: the opening of Pandora's box?British Journal of Addiction, 1992